Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent Biologics's revenue for the
six
months ended in Dec. 2025 was $1,006 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $1,835 Mil.
Innovent Biologics's Revenue per Share for the
six
months ended in Dec. 2025 was $0.57.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $1.06.
During the past 12 months, the average Revenue per Share Growth Rate of Innovent Biologics was 34.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 34.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 20.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 10 years, Innovent Biologics's highest 3-Year average Revenue per Share Growth Rate was 451.70% per year. The lowest was 9.00% per year. And the median was 42.85% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Innovent Biologics Revenue Related Terms
Innovent Biologics Revenue Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innovent Biologics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Revenue distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,835 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (IVBXF) has a Revenue of $1,835 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Innovent Biologics and its competitors.
Is Innovent Biologics' Revenue too high?
Innovent Biologics' current Revenue is $1,835 Mil. Overall, Innovent Biologics has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Revenue compare to VRTX and REGN?
Innovent Biologics' Revenue of $1,835 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current Revenue is $1,835 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $14.44, compared to a current price of $12.80 — trading 11.4% below its estimated fair value. The current Revenue is $1,835 Mil. Innovent Biologics' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Innovent Biologics (IVBXF), the current Revenue is $1,835 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (IVBXF) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of $12.80 is trading 11.4% below its estimated GF Value™ of $14.44.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for IVBXF:
Revenue: $1,835 Mil
GF Value™: $14.44 vs. price of $12.80 (11.4% below fair value)
No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
77GF Score
Get the complete analysis for IVBXF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVBXF has been successfully added to your 
